Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Jazz Pharmaceuticals plc | form8-kx2015jpm.htm |
Exhibit 99.1
Relevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the J.P. Morgan Healthcare Conference in San Francisco, California on January 12, 2015:
Bruce C. Cozadd, Chairman & CEO, Jazz Pharmaceuticals plc
. . .
I will make forward-looking statements. Of course, those are subject to risks and uncertainties that we detail in our SEC filings.
...
And last when I give financial guidance in today's presentation, that's the guidance we disclosed on November 4 on our third quarter earnings call and it's as of that date, unless I specifically update it, which I will do for certain items, okay.
. . .
Good execution of our strategy has resulted in nice top-line growth. I'm pleased to tell you today that we do expect our total revenues for 2014 will come in at the upper end of our previously provided guidance, and I'll remind you that our revenue run rate coming out of the third quarter was in excess of $1.2 billion. This would represent about 30% to 35% growth on the top line. And you can see that most of our revenues are coming from our core products, as highlighted in the pie chart on the right.
. . .
We've had continued strong performance on Xyrem and once again, I am pleased to announce that we do expect our 2014 Xyrem sales will come in at toward the upper end of our previously provided guidance. And remember, our third quarter revenues for Xyrem annualized at a run rate of $800 million -- a little north of $800 million. You'll also see on the slide that we did achieve 10% volume growth rate for Xyrem 2014 over 2013 and this in part reflects a very strong fourth quarter performance with 14% volume growth over the fourth quarter in the prior year. Now, I will say we instituted a change to refill eligibility during the fourth quarter to allow for earlier refills and some of the patients did take us up on that. We did that to ensure that we reduced the risk of any Xyrem patient going out without medications in the event of any service slowdown at our central pharmacy, which we did see in the first quarter of last year. If we back out the effect of that change, fourth quarter growth on volume would have been 11%.
. . .
I'm also pleased to say that we expect that our 2014 net sales of Erwinaze will be at the upper end of our previously given guidance, which was $190 million to $200 million and we think there is substantial growth opportunity for Erwinaze.
. . .
After acquiring this product in January and launching it in Europe in March, I'm pleased to say that once again, we expect our net sales to come in at the upper end of our previously-provided guidance. We would report $65 million to $70 million of those sales, of course pro forma for that small period at the beginning of the year where we didn't own the product yet, total revenues on a pro forma basis would be slightly higher.
. . .
So when I presented last year at this conference, I gave you a snapshot of what we expected in terms of 2014 accomplishments and I'm pleased to say it was fairly accurate.
. . .
Relevant slides from Jazz Pharmaceuticals plc's presentation at the J.P. Morgan Healthcare Conference in San Francisco, California on January 12, 2015:
